Recent Updates
Recently added Catalysts
NTRA Positive Sentiment

New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma

Tuesday, September 1, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Natera, Inc. has published new data in Blood Neoplasia, confirming the effectiveness of Signatera for minimal residual disease (MRD) assessment in lymphoma patients. This validation applies to both newly diagnosed and relapsed/refractory cases. The study highlights the limitations of traditional PET/CT scans, which have a low positive predictive value.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strong clinical validation of Signatera for MRD assessment.
  • Publication in a reputable journal enhances credibility.
  • Potential to improve treatment response assessment in lymphoma.

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT scans serve as the standard tool for assessing treatment response in lymphoma, but their performance is limited, with positive predictive value (PPV) reported as low as 50%

Frequently Asked Questions

What is Signatera used for?

Signatera is used for assessing minimal residual disease (MRD) in lymphoma patients.

Where was the new data on Signatera published?

The new data was published in the journal Blood Neoplasia.

What are the limitations of PET/CT scans in lymphoma?

PET/CT scans have a low positive predictive value, reported as low as 50%.

What types of lymphoma does the validation apply to?

The validation applies to both newly diagnosed and relapsed/refractory lymphoma.

ShareAdd on Google
Tags: NTRA Viatris Investor Conferences Healthcare Natera Signatera MRD assessment lymphoma Blood Neoplasia
Last updated: Sep 1, 2026

Biotech snapshot

Cash runway
$1092M liquidity · $0M/mo burn
Low dilution risk
Lead asset
AtezolizumabPhase 3
Muscle-invasive Bladder Cancer →